Clinical trials

Only want trials near your city that fit you? Get alerts

Disease

Country

Status

Phase

Reset

595 trials

NCT04879043
Recruiting
Study to Assess Safety of HDP-101 in Patients With Relapsed Refractory Multiple Myeloma
Phase 1/2 · Germany, Spain, Hungary, Poland, Romania, United States · 25 sites
Registry update: 17 Sept 2026
NCT05192122
Recruiting
Free From Maintenance Drug Therapy in Multiple Myeloma (The FREEDMM Trial) for Minimal Residual Disease (MRD
Phase 1 · United States · 1 site
Registry update: 18 Dec 2025
NCT04888039
Recruiting
Follow-up of Patients With Multiple Myeloma in the West-Occitanie Region "Living With a Myeloma in West-Occitanie"
Not applicable · France · 1 site
Registry update: 29 Apr 2026
2023-503404-89-00
Recruiting
A study to evaluate the Safety, Pharmacokinetics, and Activity of Subcutaneous Cevostamab (BFCR4350A) in Patients with Relapsed or Refractory Multiple Myeloma (CAMMA 3)
Phase 1 · Belgium, Greece, Italy · 6 sites
Registry update: 24 Aug 2026
NCT06636552
Recruiting
An Investigator-Initiated, Phase II, Multicenter, Open-Label, Single-Arm, Prospective Clinical Trial to Evaluate the Efficacy and Safety of Alternating Bortezomib-Based Regimens in Combination With DaratUMumab Followed by Maintenance With Daratumumab in the Frontline Setting of Primary Plasma CEll L
Phase 2 · Greece · 7 sites
Registry update: 10 Oct 2024
NCT04662294
Recruiting
CD 70 CAR T for Patients With CD70 Positive Malignant Hematologic Diseases
Early phase 1 · China · 1 site
Registry update: 4 Nov 2021
NCT04898790
Recruiting
Improving Cognitive Function in Older Adults Undergoing Stem Cell Transplant
Not applicable · United States · 1 site
Registry update: 19 Aug 2026
NCT04240054
Recruiting
Bortezomib, Isatuximab, Cyclophosphamide and Dexamethasone Induction in Transplant-Eligible Multiple Myeloma Patients With Renal Insufficiency
Phase 2 · United States · 1 site
Registry update: 28 Jan 2026
NCT05031897
Recruiting
Two Step Haplo With Radiation Conditioning
Phase 2 · United States · 1 site
Registry update: 30 Oct 2025
NCT04234022
Recruiting
Zn-DDC to Target Hypoxia-NFkappaB-CSCs Pathway in Multiple Myeloma
Not applicable · United Kingdom · 1 site
Registry update: 9 Apr 2026
NCT05020236
Recruiting
A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments
Phase 3 · Argentina, Austria, Australia, Belgium, Brazil, Canada, China, Czechia, Germany, Spain, Finland, France, United Kingdom, Greece, Italy, Japan, South Korea, Mexico, Netherlands, Norway, New Zealand, Poland, Sweden, Taiwan, United States · 229 sites
Registry update: 24 Aug 2026
Conflicting statuses (not updated in the registry for 2 months)
NCT05093335
Recruiting
In-Human CXCR4 Imaging of Hematologic and Solid Tumors Using [68Ga]-Pentixafor-PET
Early phase 1 · United States · 1 site
Registry update: 5 Feb 2026
NCT04991103
Recruiting
Minimal Residual Disease Response-adapted Deferral of Transplant in Dysproteinemia (MILESTONE)
Phase 2 · United States · 1 site
Registry update: 31 Dec 2025
NCT05243212
Recruiting
Study of CAR-BCMA, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against BCMA in Subjects With Multiple Myeloma
Phase 1/2 · Israel · 1 site
Registry update: 31 Jan 2024
NCT04973605
Recruiting
A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma
Phase 1/2 · Australia, Brazil, Canada, China, Germany, Spain, France, United Kingdom, Greece, Italy, South Korea, Singapore, United States · 80 sites
Registry update: 26 Oct 2026
NCT06099912
Recruiting
Individualized Dynamic Frailty-tailored Therapy (DynaFiT) in Elderly Patients With NDMM
Not applicable · China · 1 site
Registry update: 12 Feb 2026
NCT04910568
Recruiting
A Study Evaluating the Safety, Pharmacokinetics, and Activity of Cevostamab in Participants With Relapsed or Refractory Multiple Myeloma
Phase 1 · Australia, Canada, Czechia, Denmark, Spain, France, United Kingdom, Israel, Italy, Japan, South Korea, Poland, United States · 33 sites
Registry update: 20 Oct 2026
Conflicting statuses (updated in the registry within the last month)
NCT04776395
Recruiting
Iberdomide Alone or in Combination With Dexamethasone for the Treatment of Intermediate- or High-Risk Smoldering Multiple Myeloma
Phase 2 · United States · 1 site
Registry update: 1 Jun 2026
NCT05283993
Recruiting
A Cohort Study of Plasma Cell Disorders (PCDs) in PKUFH
Not applicable · China · 1 site
Registry update: 16 Sept 2026
NCT04558931
Recruiting
Clinical Trial for Autologus NK Cells Alone or in Combination With Isatuximab as Maintenance for Multiple Myeloma
Phase 2 · Sweden · 1 site
Registry update: 11 Oct 2023

Ordered by registry start date. Freshness and sponsorship never change the order.